Merck-Moderna Cancer Vaccine Breakthrough Ignites Healthcare Sector

A groundbreaking cancer vaccine co-developed by Merck and Moderna has shown positive results in its first-ever Phase 3 trial, significantly extending the period patients lived without melanoma returning compared to Keytruda alone.

The vaccine, combined with Merck's immunotherapy drug Keytruda, met the primary goal of the trial. This breakthrough has sent shockwaves through the healthcare sector, with Moderna's shares skyrocketing nearly 177% and Merck rising 12.60% in immediate market reaction.

With an estimated 234,680 cases of melanoma expected to be diagnosed in the United States in 2026, the global melanoma therapeutics market is projected to reach $10.27 billion by 2030, witnessing a 9.9% CAGR according to Grand View Research.

The latest development puts a spotlight on MRK and MRNA, as well as healthcare exchange-traded funds (ETFs) holding them. Investors eager to capitalize on the expected benefits of this vaccine breakthrough may want to consider gaining exposure to healthcare ETFs that hold Merck or Moderna or both.